# Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)

> **NCT05665088** · PHASE3 · TERMINATED · sponsor: **BioXcel Therapeutics Inc** · enrollment: 13 (actual)

## Conditions studied

- Agitation
- Dementia

## Interventions

- **DRUG:** BXCL501
- **DRUG:** Matching Placebo

## Key facts

- **NCT ID:** NCT05665088
- **Lead sponsor:** BioXcel Therapeutics Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-12-14
- **Primary completion:** 2023-09-11
- **Final completion:** 2023-09-11
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Study was terminated for business reasons; not due to safety or efficacy concerns
- **Last updated:** 2023-12-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05665088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05665088, "Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05665088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*